For Drug-Resistant STIs, Detection Is Not Enough
A recent article posted in Clinical Lab Products (CLP) by Professor Sepehr Tabrizi, Royal Women’s Hospital, Melbourne, describes our current understanding of Mycoplasma genitalium, the rise of treatment failure due to macrolide (e.g. azithromycin) resistance, and the need for diagnostics that can establish the antimicrobial resistance status of infections.
SpeeDx technology has advanced capabilities over current molecular tests, offering a rapid and comprehensive tool for better management of this important sexually transmitted infection.
Read the full article here